GoodRx Holdings Inc

GoodRx Holdings Inc(GDRX)の株式分析

$3.360

-0.139 (-4.14%)終値時点

Loading chart…
高値
3.495
始値
3.480
出来高加重平均価格
3.40
出来高
848.20K
時価総額
2.89B
安値
3.330
売買代金
2.88M
EV/EBITDA(TTM)
7.68

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

investors.goodrx.com

AI分析 of GoodRx Holdings Inc (GDRX)

中立

GoodRx Holdings Inc (GDRX) is currently trading at $3.36, below the average analyst target of $3.73, indicating potential upside. However, the RSI is at 46.195, suggesting the stock is neither overbought nor oversold. The forward P/E ratio of 10.29 is attractive compared to the current P/E of 73.59, indicating potential undervaluation. The main risk is the significant decline in net income to $1.17 million in Q1 2026 from $12.84 million in Q2 2025, reflecting profitability challenges.

バリュエーション指標

GoodRx Holdings Inc(GDRX)の現在の予想PERは10.29で、5年平均は36.51です。

予想PER

適正
5年平均 P/E
36.51
現在のP/E
10.29
割高
644.96
割安
-571.94

予想EV/EBITDA

適正
5年平均 EV/EBITDA
12.97
現在のEV/EBITDA
7.68
割高
25.17
割安
0.76

予想PSR

適正
5年平均 P/S
3.64
現在のP/S
1.43
割高
7.30
割安
-0.03

Alphio AI による GDRX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%GDRX

$4.23

シナリオ価格

基

基本

基本 · 50%GDRX

$3.42

シナリオ価格

弱

弱気

弱気 · 25%GDRX

$3.21

シナリオ価格

GDRX を保有するクジラ

S

Silver Lake Technology Management, L.L.C.

+ を保有GDRX

+14.72%

3か月リターン

T

TCMI Inc.

+ を保有GDRX

+1.93%

3か月リターン

イベントタイムライン

2026-09-03 (ET)

09:30:00

GoodRx Launches Family Plan for $24.99 Monthly

2026-08-05 (ET)

17:31:00

GoodRx Q2 Revenue $200.4M, Exceeds Consensus

17:30:00

Raises FY26 Adjusted EBITDA Outlook to $240M-$250M

2026-05-27 (ET)

09:10:00

GoodRx Launches GoodRx Companion Subscription at $14.99 per Month

2026-05-06 (ET)

17:10:00

Raises FY26 Adjusted EBITDA Outlook to Over $235M

ニュース

GDRX のよくある質問 — Alphio AI が回答

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications. It operates in the Technology sector (SERVICES-COMPUTER PROCESSING & DATA PREPARATION industry).

GoodRx Holdings Inc (GDRX) is currently trading at $3.36, below the average analyst target of $3.73, indicating potential upside. However, the RSI is at 46.195, suggesting the stock is neither overbought nor oversold. The forward P/E ratio of 10.29 is attractive compared to the current P/E of 73.59, indicating potential undervaluation. The main risk is the significant decline in net income to $1.17 million in Q1 2026 from $12.84 million in Q2 2025, reflecting profitability challenges.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める